This site is intended for healthcare professionals
Insight

Your guide to IBD novel treatments and assessment tools

Read time: 1 mins
Last updated:6th Mar 2019
Published:5th Mar 2019
Source: Pharmawand

UEG Week 2018 saw a host of insights and symposia surrounding the assessment and treatment of Irritable Bowl Disease (IBD). Our expert faculty explored these recent advances and looked at the potential impact that biosimilars could have. Below is a round up of some of the key findings for you to explore for free at your own convenience.

Symposium highlights

New assessment tools in IBD may change your clinical practice. In this educational symposium 'Current IBD Management Strategies: Role of disease assessment' our expert faculty discuss assessment tools including the IBD index, and more. Watch the symposium here 

 

Bitesize expert opinion

Hear from Dr Krisztina Gecse, distilling best practice use of currently available assessment tools, the role that biomarkers can play, and the potential of biosimilars to alter the current treatment paradigm. Watch the interviews

 

The view from UEG Week 2018

Review the report and analysis from a packed UEGW Vienna as we present daily reviews compiled by our team of scientific writers. Read the reports here

 

Visit the inflamatory bowel disease assessment tool learning zone 

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.